Rakovina Therapeutics Announces Share Consolidation Effective Date

Core Points - Rakovina Therapeutics Inc. will implement a share consolidation effective June 24, 2025, at a ratio of one post-consolidation share for every ten pre-consolidation shares [1][2] - The new common shares will trade on the TSX Venture Exchange under the existing symbol "RKV" starting June 24, 2025, with a new CUSIP number 75103L309 and ISIN number CA75103L3092 [2] - The company will have approximately 21,148,038 common shares issued and outstanding post-consolidation [2] Shareholder Instructions - The company's transfer agent, Odyssey Trust Company, will send a letter of transmittal to registered shareholders for exchanging pre-consolidation share certificates for post-consolidation certificates [4] - Fractional shares resulting from the consolidation will be rounded up or down based on the specified criteria [2] Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using unique technologies for targeting the DNA-damage response, powered by Artificial Intelligence [6] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [7]